Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Applied BioCode Granted Additional Patent for Barcoded Magnetic Beads Used for Multiplex MDx Assays

Applied BioCode Inc.
Posted on: 04 Apr 12

Applied BioCode, Inc. today announced that the United States Patent and Trademark Office has issued US Patent #8,148,139 (April 03, 2012) "Light Transmitted Assay Beads," describing the method of use and manufacturing of its Barcoded Magnetic Beads (BMB) products.

“The patent further expands the scope of our earlier patents, #7,858,307 (Dec 28, 2010) and #7,871,770 (Jan 18, 2011), for the development of polymer-based Barcoded Magnetic Beads, which offer excellent biocompatibility and long-term stability properties,” said Winston Ho, PhD, President of Applied BioCode. “These patents are important components of our intellectual property portfolio, specifically covering our encoded polymer bead technology licensed initially from Maxwell Sensors, Inc. These patents will provide our products with long-term market value.”

Because Barcoded Magnetic Beads exhibit very high contrast barcode patterns, the barcodes can be decoded easily and very accurately. The multiplexing is readily increased by adding additional barcode digits to the BMB’s. The 12-digit micro bead has 4,096 separate barcodes, enabling the simultaneous analysis of up to 4,096 DNA or protein targets in a small amount of sample. The BMB and associated BioCode analyzers provide clinical and life science research laboratories with a wide variety of biological applications including molecular diagnostics, immunoassays, gene mutation analysis, biomarker validation & discovery, drug resistance genotyping, and pharmacogenomics.

About Applied BioCode, Inc.

Applied BioCode, Inc., a privately heldbiotechnology company with headquarters located in Santa Fe Springs, California, develops, manufactures, and markets products to assist those focused on molecular diagnostics, bioresearch, and biomarkers validation. The BMB is a single platform which can be utilized from Biomarker Discovery directly to In-Vitro Diagnostics. This approach enables users to optimize efficiency and resources to help customers maximize the benefit of digital multiplexing.

Business Wire

Last updated on: 04/04/2012

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.